Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec up for sale

Executive Summary

Biogen Idec hires Goldman Sachs and Merrill Lynch to evaluate third party interest, including activist investor Carl Icahn, in acquiring the biotechnology firm, according to an Oct. 12 announcement. Biogen has a market capitalization of about $20 bil. and sports a portfolio that includes multiple sclerosis products Avonex (interferon beta-1a) and Tysabri (natalizumab), as well as the non-Hodgkin's lymphoma treatment Rituxan (rituximab), which it co-markets with Genentech...
Advertisement

Related Content

Biogen Idec has no buyer
Advertisement
UsernamePublicRestriction

Register

PS048901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel